Can you stay on 7.5mg Mounjaro for weight loss long-term?

You've been on 7.5mg for a month and you're not sure what happens next

Picture this: you collected your second 7.5mg pen, the nausea from the 5mg-to-7.5mg step has mostly settled, and your appetite is noticeably lower. The question sitting in the back of your head is whether you're supposed to move up again automatically, or whether you can just... stay here for a while. The honest answer is that there is no automatic escalator. Tirzepatide's licensed schedule moves through 2.5mg increments roughly every four weeks, but "roughly" and "every" are both guided by your prescriber's assessment of how you are doing. If 7.5mg is working (meaning weight is shifting, side effects are manageable, and you feel well on it) there is a reasonable clinical case for holding the dose.

The 7.5mg dose in the context of Mounjaro's weight-loss profile sits in the middle of the licensed range, and trial data from the SURMOUNT programme showed that meaningful weight reduction happens well before participants reached 15mg. Every dose is a working dose, not a waiting room. If you want to understand the full dose arc before your next review, the Mounjaro dosing guide for weight loss covers what the schedule looks like from start to finish.

What "staying at a dose" actually means for your treatment

Holding a dose is a clinical decision, not a shortcut or a failure. There are several legitimate reasons a prescriber might agree that 7.5mg is the right place to remain. First, tolerability: if the step from 5mg to 7.5mg brought significant nausea or gut symptoms, giving your body longer to adjust is medically sensible rather than rushing upward. Second, response: some people lose weight steadily at 7.5mg without plateauing, in which case the risk-benefit of increasing is less clear. Third, practical context: a surgical procedure booked for next month, a fortnight's holiday where refrigerating your pen will be complicated, or a particularly demanding few weeks at work can all be factors worth raising with your prescriber.

On that last point, timing does matter more than people expect. A number of patients plan their repeat orders around payday or a quieter Monday, which is entirely sensible, but clinical reviews are equally worth timing around life events. Starting a dose increase the week before major surgery, for instance, is the kind of scenario your prescriber will want to know about. The full Mounjaro overview explains how the clinical review process works at each repeat. Side effects when titrating are covered in the dedicated resource on managing nausea at lower Mounjaro doses, which applies to the 7.5mg step too.

What staying at a dose does not mean: indefinite treatment without review. Your prescriber checks progress at every repeat order. According to NICE's technology appraisal of tirzepatide (TA1026), if less than 5% body weight has been lost after six months at the highest tolerated dose, continuing treatment should be reviewed. That is a threshold worth knowing, though your own assessment happens in dialogue with your prescriber, not against a single number in isolation.

When the conversation should probably tip toward moving up

There are also situations where staying at 7.5mg may not serve you as well over time. If weight loss has plateaued for eight to twelve weeks and you are tolerating the dose without significant side effects, the clinical rationale for increasing is stronger. The doses above 7.5mg (10mg, 12.5mg and 15mg) exist precisely because the relationship between dose and weight loss in tirzepatide trials was broadly dose-dependent: higher doses produced greater average reductions across the SURMOUNT programme, published in the New England Journal of Medicine. That does not mean 15mg is everyone's destination, but it does mean a plateau at 7.5mg is a reasonable trigger for a clinical conversation about whether to try the next step.

It is also worth knowing that you can return to a lower dose after a period at a higher one if side effects become problematic. The licensed schedule is not a one-way ratchet. Some people find they settle at 10mg after trying 12.5mg; others discover that 7.5mg remains their personal sweet spot when they come back to it. People who started treatment at a lower dose (there's useful context in the guide on whether 5mg is a viable long-term dose) sometimes find their individual tolerance point is simply lower than the licensed ceiling, and that is not a treatment failure.

How to raise this with your prescriber at your next review

The most useful thing you can bring to any clinical review is a clear account of three things: how much weight you have lost since starting 7.5mg, how your side effects have changed since the dose increase, and whether there are any life circumstances that affect your treatment right now. Your prescriber at a regulated pharmacy works through exactly these factors, it is the same assessment whether you're asking to stay put, step up or step back. The NHS patient information page for tirzepatide outlines what the medicine is and is not suitable for, which is useful background before your review.

If you have questions about what private treatment involves, including what a consultation covers and what ongoing aftercare looks like, the nume FAQs give a plain-English overview. And if cost is a factor in how you're thinking about your dose (whether staying at 7.5mg is cheaper than moving up) the Mounjaro cost breakdown explains how private pricing works by dose. Speak to our prescribers if you'd like a clinical review of where you are in your treatment: start with a free consultation.